Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-22T07:57:14.701Z Has data issue: false hasContentIssue false
  • English
  • Français

Ziprasidone as an Augmenting Agent in the Treatment of Anxiety-Spectrum Disorders

Published online by Cambridge University Press:  07 November 2014

Daniel L. Crane
Get access Rights & Permissions [Opens in a new window]

Abstract

Anxiety disorders are currently one of the most common health concerns in the United States. Overall, they are the single largest cost to the healthcare system. They are also underdiagnosed and undertreated. Selective serotonin reuptake inhibitors and benzodiazepines appear to be the most common pharmacologic treatment approaches. Unfortunately, not all patients respond to these treatments. Many augmentation strategies have been tried in the past with varying levels of success or safety. This article describes a safe and highly effective augmentation technique in patients suffering from some of the most serious and debilitating forms of anxiety disorders, namely obsessive-compulsive disorder and panic disorder.

Type
Case Report
Information
CNS Spectrums , Volume 10 , Issue 3 , March 2005 , pp. 176 - 179
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Lepine, JP. The epidemiology of anxiety disorders: prevalence and societal costs. J Clin Psychiatry. 2002;63(suppl 14):4–8.Google ScholarPubMed
2. Katon, W. Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. J Clin Psychiatry. 1996;57(suppl 10): 11–18.Google Scholar
3. Mendlowicz, MV, Stein, MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry. 2000;157:669–682.CrossRefGoogle ScholarPubMed
4. Uhlenhuth, EH, Baiter, MB, Ban, TA, Yang, K. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress Anxiety. 1999;9:107–116.3.0.CO;2-T>CrossRefGoogle Scholar
5. Goodman, WK, Price, LH, Rasmussen, SA, Delgado, PL, Heninger, GR, Charney, DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989;46:36–44.Google Scholar
6. Roy-Byrne, P, Cowley, DS. Clinical approach to treatment-resistant panic disorder. In: Rosenbaum, JF, Pollack, MH, eds. Panic Disorder and its Treatment. New York, NY: Marcel Dekker; 1998;205–227.Google Scholar
7. Coplan, JD, Tiffon, L, Gorman, JM. Therapeutic strategies for the patient with treatment-resistant anxiety. J Clin Psychiatry. 1993;54 (suppl):69–74.Google Scholar
8. Hollander, E, Beinstock, CA, Koran, LM, et al. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry. 2002;63(suppl 6):20–29.Google ScholarPubMed
9. Marazziti, D, Pallanti, S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry. 1999;156:1834–1835.Google Scholar
10. Etxebeste, M, Aragues, E, Malo, P, Pacheco, L. Olanzapine and panic attacks. Am J Psychiatry. 2000;157:659–660.Google Scholar
11. Marusic, A, Farmer, A. Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder. Br J Psychiatry. 2000;177:567.Google Scholar
12. Sun, TF, Lin, PY, Wu, CK. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases. Chang Gung Med J. 2001;24:587–592.Google Scholar
13. Mohr, N, Vythilingum, B, Emsley, RA, Stein, DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2002;17:37–40.Google Scholar
14. Saxena, S, Wang, D, Bystritsky, A, Baxter, LR Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry. 1996;57:303–336.Google Scholar
15. Weiss, EL, Potenza, MN, McDougle, CJ, Epperson, CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry. 1999;60:524–527.Google Scholar
16. Koran, LM, Ringold, AL, Elliott, MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2000;61:514–517.CrossRefGoogle ScholarPubMed
17. Pfanner, C, Marazziti, D, Dell'Osso, L, et al. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol. 2000;15:297–301.Google Scholar
18. Francobandiera, G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open-study. Can J Psychiatry. 2001;46:356–358.Google Scholar
19. Denys, D, van Megen H, , Westenherg, H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder, an open-label study. J Clin Psychiatry. 2002;63:700–703.CrossRefGoogle ScholarPubMed
20. D'Amico, G, Cedro, C, Muscatello, MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmocol Biol Psychiatry. 2003;27:619–623.CrossRefGoogle ScholarPubMed
21. Atmaca, M, Kuloglu, M, Tezcan, E, Gecici, O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol. 2002;17:115–119.CrossRefGoogle ScholarPubMed
22. McDougle, CJ, Epperson, CN, Pelton, GH, Wasylink, S, Price, LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794–801.Google Scholar
23. Hollander, E, Rossi, NB, Sood, E, Pallanti, S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003;6:397–401.Google Scholar
24. Takahashi, H, Higuchi, H, Shimizu, T. Full remission of panic attacks in a schizophrenic patient after switching from haloperidol to risperidone. J Neuropsychiatry Clin Neurosci. 2001;13:113–114.Google Scholar
25. Khaldi, S, Komreich, C, Dan, B, Pelc, L. Usefulness of olanzapine in refractory panic attacks. J Clin Psychopharmacol. 2003;23:100–101.Google Scholar
26. Matthew, SJ, Coplan, JD, Gorman, JM. Management of treatment-refractory panic disorder. Psychopharmacol Bull. 2001;35:97–110.Google Scholar
27. Takahashi, H, Sugita, T, Yoshida, K, Higuchi, H, Shimizu, T. Effect of quetiapine in the treatment of panic attacks in patients with schizophrenia: 3 case reports. J Neuropsychiatry Clin Neurosci. 2004;16:113–115.CrossRefGoogle ScholarPubMed
28. Mottard, JP, de la Sablonniere, JF. Olanzapine-induced obsessive-compulsive disorder. Am J Psychiatry, 1999;156:799–800.Google Scholar
29. Khullar, A, Chue, P, Tibbo, P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci. 2001;26:55–59.Google Scholar
30. Alevizos, B, Lykouras, L, Zervas, IM, Christodoulou, GN. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci. 2001;26:55–59.Google Scholar
31. Alevizos, B, Lykouras, L, Zervas, IM, Christodoulou, GN. Risperidune-induced obsessive-compulsive symptoms: a series of six cases. J Clin Psychopharmacol. 2002;22:461–467.Google Scholar
32. Diler, RS, Yolga, A, Avci, A, Scahill, L. Risperidone-induced obsessive-compulsive symptoms in two children. J Child Adolesc Psychopharmacol. 2003;13(suppl 1):S89–S92.Google Scholar
33. Levy, E, Margolese, HC, Sultan, S. Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine. Can J Psychiatry. 2003;48:709–710.Google Scholar
34. Morrison, D, Clark, D, Goldfarb, E, McCoy, L. Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psychiatry. 1998;155:855.Google Scholar
35. Lykouras, L, Zervas, IM, Gournellis, R, Malliori, M, Rabavilas, A. Olanzapine and obsessive-compulsive symptoms. Eur Neuropsychopharmacol. 2000;10:385–387.Google Scholar
36. Schmidt, AW, Lebel, LA, Howard, HR Jr, Zom, SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425;197–201.Google Scholar
37. Tatsumi, M, Jansen, K, Blakely, RD, Richelson, E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999;368:277–283.CrossRefGoogle ScholarPubMed
38. Richelson, E, Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29–39.Google Scholar
39. Ability [package insert]. Rockville, Md: Otsuka America Pharmaceutical, Inc; 2004.Google Scholar
40. Rollema, H, Lu, Y, Schmidt, AW, Sprouse, JS, Zorn, SH. 5-HT(lA) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000;48:229–237.Google Scholar
41. Arato, M, O'Connor, R, Meltzer, HY; ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17:207–215.Google Scholar
42. Wilner, KD, Anziano, RJ, Johnson, AC, Miceli, JJ, Fricke, JR, Titus, CK. The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol. 2002;22:206–210.Google Scholar
43. Tarsy, D, Baldessarini, RJ, Tarazi, FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16:23–45.Google Scholar
44. Taylor, DM, McAskill, R. Atypical antipsychotics and weight gain–a systematic review. Acta Psychiatr Scand. 2000;101:416–432.CrossRefGoogle ScholarPubMed
45. Tandon, R. Safety and tolerability: how do newer generation “atypical” antipsychotics compare? Psychiatr Q. 2002;73:297–311.Google Scholar
46. Weiden, PJ, Daniel, DG, Simpson, G, Romano, SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:595–600.Google Scholar
47. Marder, SR, Essock, SM, Miller, AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334–1349.Google Scholar
48. Stahl, SM, Shayegan, DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(suppl 19):6–12.Google Scholar
49. Mamo, D, Kapur, S, Shammi, CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818–825.Google Scholar